Alendronate-Loaded Modified Drug Delivery Lipid Particles Intended for Improved Oral and Topical Administration

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2016 Jul 2

PMID 27367664

Citations 10

Authors

Lacramioara Ochiuz

Cristian Grigoras

Marcel Popa

Iulian Stoleriu

Corneliu Munteanu

Daniel Timofte

Lenuta Profire

Anca Giorgiana Grigoras

Affiliations

Soon will be listed here.

Abstract

The present paper focuses on solid lipid particles (SLPs), described in the literature as the most effective lipid drug delivery systems that have been introduced in the last decades, as they actually combine the advantages of polymeric particles, hydrophilic/lipophilic emulsions and liposomes. In the current study, we present our most recent advances in the preparation of alendronate (AL)-loaded SLPs prepared by hot homogenization and ultrasonication using various ratios of a self-emulsifying lipidic mixture of Compritol 888, Gelucire 44/14, and Cremophor A 25. The prepared AL-loaded SLPs were investigated for their physicochemical, morphological and structural characteristics by dynamic light scattering, differential scanning calorimetry, thermogravimetric and powder X-ray diffraction analysis, infrared spectroscopy, optical and scanning electron microscopy. Entrapment efficacy and actual drug content were assessed by a validated HPLC method. In vitro dissolution tests performed in simulated gastro-intestinal fluids and phosphate buffer solution pH 7.4 revealed a prolonged release of AL of 70 h. Additionally, release kinetics analysis showed that both in simulated gastrointestinal fluids and in phosphate buffer solution, AL is released from SLPs based on equal ratios of lipid excipients following zero-order kinetics, which characterizes prolonged-release drug systems.

Citing Articles

Alendronate as Bioactive Coating on Titanium Surfaces: An Investigation of CaP-Alendronate Interactions.

Despotovic I, Petrovic Z, Katic J, Mikic D Materials (Basel). 2024; 17(11).

PMID: 38893965 PMC: 11173899. DOI: 10.3390/ma17112703.

Polydopamine-Modified Titanium Dioxide Nanotube Arrays Doped with Calcium as a Sustained Drug Delivery System.

Wu L, Wu X, Wu L, Chen D, Zhang T, Zheng H ACS Omega. 2024; 9(4):4949-4956.

PMID: 38313478 PMC: 10831826. DOI: 10.1021/acsomega.3c08772.

Self-emulsifying micelles as a drug nanocarrier system for itraconazole oral bioavailability enhancement; and assessment.

Islam N, Khan N, Razzaq A, Khan Z, Menaa F, Alfaifi M Saudi Pharm J. 2023; 31(12):101839.

PMID: 37965489 PMC: 10641562. DOI: 10.1016/j.jsps.2023.101839.

Fabrication of Celecoxib PVP Microparticles Stabilized by Gelucire 48/16 via Electrospraying for Enhanced Anti-Inflammatory Action.

Alshawwa S, El-Masry T, Elekhnawy E, Alotaibi H, Sallam A, Abdelkader D Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259403 PMC: 9960083. DOI: 10.3390/ph16020258.

Formulation and Evaluation of Niosomal Alendronate Sodium Encapsulated in Polymeric Microneedles: In Vitro Studies, Stability Study and Cytotoxicity Study.

Zaid Alkilani A, Abu-Zour H, Alshishani A, Abu-Huwaij R, Basheer H, Abo-Zour H Nanomaterials (Basel). 2022; 12(20).

PMID: 36296760 PMC: 9611853. DOI: 10.3390/nano12203570.

References

Katsumi H, Nakatani M, Sano J, Abe M, Kusamori K, Kurihara M . Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats. Int J Pharm. 2010; 400(1-2):124-30. DOI: 10.1016/j.ijpharm.2010.08.041. View

Cremers S, Papapoulos S . Pharmacology of bisphosphonates. Bone. 2011; 49(1):42-9. DOI: 10.1016/j.bone.2011.01.014. View

Bock O, Felsenberg D . Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging. 2008; 3(2):279-97. PMC: 2546473. DOI: 10.2147/cia.s2134. View

Doktorovova S, Souto E, Silva A . Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - a systematic review of in vitro data. Eur J Pharm Biopharm. 2014; 87(1):1-18. DOI: 10.1016/j.ejpb.2014.02.005. View

Kim H, Fassihi R . Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. J Pharm Sci. 1997; 86(3):323-8. DOI: 10.1021/js960307p. View

Rosca I, Watari F, Uo M . Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J Control Release. 2004; 99(2):271-80. DOI: 10.1016/j.jconrel.2004.07.007. View

Bose S, Du Y, Takhistov P, Michniak-Kohn B . Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. Int J Pharm. 2012; 441(1-2):56-66. DOI: 10.1016/j.ijpharm.2012.12.013. View

Black D, Bauer D, Schwartz A, Cummings S, Rosen C . Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?. N Engl J Med. 2012; 366(22):2051-3. PMC: 4015798. DOI: 10.1056/NEJMp1202623. View

Merisko-Liversidge E, Liversidge G . Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008; 36(1):43-8. DOI: 10.1177/0192623307310946. View

10.

Parveen S, Misra R, Sahoo S . Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2011; 8(2):147-66. DOI: 10.1016/j.nano.2011.05.016. View

11.

Miladi K, Sfar S, Fessi H, Elaissari A . Drug carriers in osteoporosis: preparation, drug encapsulation and applications. Int J Pharm. 2013; 445(1-2):181-95. DOI: 10.1016/j.ijpharm.2013.01.031. View

12.

Mehnert W, Mader K . Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47(2-3):165-96. DOI: 10.1016/s0169-409x(01)00105-3. View

13.

Binkley N, Ringe J, Reed J, Ljunggren O, Holick M, Minne H . Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. Bone. 2009; 44(4):639-47. DOI: 10.1016/j.bone.2008.05.002. View

14.

Gagliardi M, Bardi G, Bifone A . Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the CNS. Ther Deliv. 2012; 3(7):875-87. DOI: 10.4155/tde.12.55. View

15.

Batrakova E, Kabanov A . Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release. 2008; 130(2):98-106. PMC: 2678942. DOI: 10.1016/j.jconrel.2008.04.013. View

16.

Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M, Valizadeh H . Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2014; 117:21-8. DOI: 10.1016/j.colsurfb.2014.01.055. View

17.

Barratt G . Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci. 2003; 60(1):21-37. PMC: 11138927. DOI: 10.1007/s000180300002. View

18.

Sahoo S, Parveen S, Panda J . The present and future of nanotechnology in human health care. Nanomedicine. 2007; 3(1):20-31. DOI: 10.1016/j.nano.2006.11.008. View

19.

Asikoglu M, Ozguney I, Ozcan I, Orumlu O, Guneri T, Koseoglu K . The absorption of (99m)Tc-alendronate given by rectal route in rabbits. Pharm Dev Technol. 2008; 13(3):213-20. DOI: 10.1080/10837450801949509. View

20.

Gohel M, Sarvaiya K, Shah A, Brahmbhatt B . Mathematical approach for the assessment of similarity factor using a new scheme for calculating weight. Indian J Pharm Sci. 2010; 71(2):142-4. PMC: 2839401. DOI: 10.4103/0250-474X.54281. View